Other languages Marinus Pharmaceuticals, Inc. Deutsche Boerse AG

Equities

61Y

US56854Q2003

Market Closed - Deutsche Boerse AG Other stock markets 11:36:05 14/06/2024 am IST			5-day change	1st Jan Change
1.31 ^EUR	-0.76%		-2.24%	-86.56%

06/06	Marinus Pharmaceuticals, Inc. Enter into an Amendment to Its Previously Disclosed Credit Agreement with Oaktree Fund Administration, Llc	CI
17/05	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Mixed Late Afternoon	18/05
Sector Update: Health Care	18/05
Marinus Completes Enrollment in Tuberous Sclerosis Complex Trial; Gets New Patent	17/05
Marinus Pharmaceuticals, Inc. Announces Key Business Updates for Tuberous Sclerosis Complex Program	17/05
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024	08/05
Marinus Pharmaceuticals, Inc. Provides Update on the Phase 3 RAISE Trial	15/04
Marinus Pharmaceuticals Ztalmy Gains Approval From UK Medicines and Healthcare Products Regulatory Agency	07/03
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday	06/03
Marinus Pharmaceuticals Q4 Net Loss Wider Than Expected While Revenue Misses Forecast; Shares Drop Premarket	06/03
Marinus Pharmaceuticals Q4 Net Loss Narrows, Revenue Higher; Shares Plunge After-Hours	06/03
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03
Marinus Pharmaceuticals, Inc. Provides Earnings Guidance for 2024	06/03
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	06/03
DiaMedica Therapeutics Names Lorianne Masuoka as Chief Medical Officer	23/01
Marinus Pharmaceuticals Raises 2023 Product Revenue Expectation	05/01
Marinus Pharmaceuticals, Inc. Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results from the Second Generation Formulation MAD Study	21/11
Marinus Pharmaceuticals inicia un programa de acceso global para ZTALMY® (ganaxolona) en suspensión oral CV	07/11
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11
Marinus Pharmaceuticals, Inc. Updates Revenue Guidance for the Fiscal Year 2023	07/11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Marinus Pharmaceuticals, Inc. Deutsche Boerse AG

Equities

61Y

US56854Q2003

Other languages

Filters